OPERON ELEVATEPLUS | DRUG-DEVICE COMBINATION PRODUCTS DOCUMENTATION
Drug-Device Combination Product Registration in Algeria – Regulatory & Development Consulting
Operon Strategist provides specialized consulting for drug-device combination products, supporting manufacturers and importers in Algeria through complex regulatory pathways. We assist in defining Primary Mode of Action (PMOA), preparing compliant design and development documentation, managing cross-disciplinary risks, and compiling submission-ready technical files that satisfy both international standards and Algeria’s ANPP (Agence Nationale des Produits Pharmaceutiques) requirements.
Our integrated approach aligns pharmaceutical and medical device regulations—reducing uncertainty, ensuring audit readiness, and accelerating market access across domestic and global markets.
Take the next step
Operon ElevatePlus
Drug-Device Combination Products Documentation Service Portfolio
Regulatory Strategy & Product Classification
Determine drug-device combination product classification and regulatory applicability
Identify applicable regulatory pathways under FDA 21 CFR Part 4, 21 CFR Part 820/QMSR, EU MDR 2017/745, ISO 13485, ISO 14971 & ICH guidelines
Assess Primary Mode of Action (PMOA) and lead regulatory authority
Develop market-specific regulatory and approval strategy roadmap
Design & Development Documentation
Design planning, user needs, design inputs & outputs documentation
Design transfer, change control, Structured Design History File (DHF) & Device Master Record (DMR) documentation
Design verification, validation & design review documentation support
Technical File, Design Dossier & Product Specifications File preparation for global compliance
Risk Management & Quality Systems
ISO 14971-compliant Risk Management File, hazard identification & risk analysis
Use-related risk analysis, FMEA/dFMEA/pFMEA & Fault Tree Analysis (FTA)
Benefit-risk evaluation, risk control, residual risk & post-production risk review
IEC 62366-1 usability engineering, human factors & formative/summative studies
GSPR & Essential Requirements Compliance
EU MDR Annex I General Safety & Performance Requirements (GSPR) checklist preparation
Mapping of applicable standards, testing evidence & compliance documentation
Essential Requirements Checklist support for legacy MDD products
GSPR compliance review aligned with EU MDR technical documentation requirements
Technical Documentation & Validation Support
Product description, intended use, formulation & device specification documentation
Clinical evaluation, clinical evidence, performance testing & software documentation
Biocompatibility, sterilization, packaging & shelf-life validation documentation
Labeling, IFU, CAPA, complaint handling, PMS & PMCF documentation support
Article 117 of EU MDR 2017/745 amends Directive 2001/83/EC & Notified Body Opinion (NBOp) Support
Article 117 of EU MDR 2017/745 amends Directive 2001/83/EC applicability assessment for medicinal products with device components
Technical documentation, GSPR, risk management & usability evidence compilation
Coordination with Notified Bodies (NB) and deficiency response support
Support for NB review of design, clinical, IFU, sterility & packaging validation documentation
What Sets Us Apart
Global exposure, structured thinking, and execution-ready expertise
Extensive Experience Across Drug, Device & Combination Product Regulations
Expertise in FDA 21 CFR Part 4, 21 CFR Part 820, ISO 13485, & EU MDR Requirements
Global Consulting Support from Concept Development to Regulatory Submission
Proven Capability in Risk Management, CAPA, DHF & Audit Readiness
Regulatory Strategy for Combination Products in Algeria – We support pharmaceutical and MedTech manufacturers in navigating dual-compliance challenges. From assessing EU MDR Article 117 requirements and obtaining Notified Body Opinions (NBOp) for export, to aligning QMS processes with FDA 21 CFR Part 4 and structuring local homologation dossiers for the ANPP, our end-to-end consulting reduces regulatory risk and speeds up market approval for prefilled syringes, inhalers, and co-packaged products.
Operon Drug-Device Combination Products Documentation Advantage
Expert regulatory strategy, design control, and compliance support for drug-device combination products under global regulatory frameworks such as FDA and EU MDR
End-to-End Regulatory Consulting for Drug-Device Combination Products
Integrated Approach Covering Both Drug & Device Compliance Requirements
Strong Alignment with Quality Management & Design Control Systems
Audit-Ready Documentation & Regulatory Submission Support
You Might Also Be Interested in
frequently asked questions
What constitutes a drug-device combination product?
A drug-device combination product is a therapeutic and diagnostic product that combines a drug, a medical device, and/or a biologic. Common examples include prefilled syringes, asthma inhalers, drug-eluting stents, and transdermal patches. They can be physically integrated (single-entity), co-packaged, or cross-labeled for use together.
How does Algeria's ANPP regulate drug-device combination products?
In Algeria, the ANPP (Agence Nationale des Produits Pharmaceutiques) oversees both pharmaceutical products and medical devices. The regulatory pathway for a combination product depends on its Primary Mode of Action (PMOA). If the primary action is pharmacological, it is generally regulated as a drug with specific device safety requirements; if mechanical, it is regulated as a medical device under homologation decrees.
What is EU MDR Article 117, and how does it affect Algerian manufacturers?
Article 117 of the EU MDR (2017/745) amended the European medicinal directive. For Algerian manufacturers exporting single-integral combination products (like prefilled syringes) to Europe, where the drug is the primary mode of action, you must now obtain a Notified Body Opinion (NBOp) confirming that the device component meets the General Safety and Performance Requirements (GSPR) of the MDR.
How do quality system requirements differ for combination products?
Combination products require manufacturers to adhere to both pharmaceutical and medical device quality standards. For example, under U.S. FDA regulations (21 CFR Part 4), manufacturers must demonstrate compliance with both drug Current Good Manufacturing Practices (cGMP) and medical device Quality System Regulations (QSR/QMSR), often achieved through a streamlined, integrated Quality Management System.
How can Operon Strategist assist with combination product registration in Algeria?
We provide end-to-end consulting, from determining the correct regulatory classification and PMOA to compiling the technical dossier. Our team bridges the gap between ISO 13485 design controls, pharmaceutical GMP, FDA guidance, and local ANPP submission requirements, ensuring a smooth and compliant path to market.
Planning a Drug-Device Combination Product Approval
Talk to a combination product expert